CTA is pleased to support the recent publication by Hitchen N, Shahnam A, Manoharan S et al, reviewing trends in Phase 1 oncology clinical trials across Australia.
This paper presents analyses of data held on the ClinicaTrials.gov database and provides both evidence of an increase in the overall number of Phase 1 clinical trials, and insight into the growing prevalence of emerging biotechs, predominantly within the Asia-Pacific area
These findings echo the recent experience of early phase trial growth within CTA; we have witnessed with keen interest the changing landscape of clinical trials nationally, especially in the Asia-Pacific and further abroad. Clinical trials are a critical step in the research and development process for new drugs, vaccines, medical devices, and diagnostics. Patients in clinical trials obtain early access to potentially life-saving treatments or medical interventions, while at the same time advancing medical knowledge. More broadly, early phase clinical trial activity contributes to the development of a thriving research culture and promotes Australia’s international research profile.
The publication abstract is available here: https://pubmed.ncbi.nlm.nih.gov/38923830/
For a copy of the full publication, please email Kurt Lackovic at [email protected]